Time-dependent effects on coronary remodeling and epicardial conductance after intracoronary injection of enriched hematopoietic bone marrow stem cells in patients with previous myocardial infarction
- PMID: 18293890
- DOI: 10.3727/096368907783338244
Time-dependent effects on coronary remodeling and epicardial conductance after intracoronary injection of enriched hematopoietic bone marrow stem cells in patients with previous myocardial infarction
Abstract
Bone marrow (BM) cells may interact with coronary endothelium and modulate coronary atherosclerosis. We investigated the time course of coronary luminal loss and changes in conductance after intracoronary injection of enriched hematopoietic BM stem cells in patients with previous myocardial infarction (MI). Among 24 patients with acute MI, 13 were randomized to early (<7 days) and 11 to late (4 months) intracoronary injection of CD133+ cells after the infarction. Segmental quantitative coronary angiography and fractional flow reserve (FFR) measurements of the infarct-related (IR) artery (A) and contralateral artery (control) were performed. In the early group, at 4 months, cumulative luminal loss (LL) of the minimal luminal diameter (MLD) of the IRA distal to the stented segment was -0.39 (-0.51-0.10) mm (p < 0.05 vs. control). There was no further change in LL between 4 and 8 months [-0.09 (-0.26-0.15) mm]. In parallel, FFR decreased at 4 months [-0.16 (-0.26-0.001), p < 0.05 vs. control] but slightly increased from 4 to 8 months follow-up [+0.05 (-0.10-0.09)]. In the late group, LL of the MLD of the IRA distal to the stented segments was -0.12 (-0.47-0.07) mm (NS vs. control) at 4 months and further -0.07 (-0.25-0.05) mm (NS) between 4 and 8 months. At 8 months, the total LL of the MLD in the early and late group was only slightly higher compared to control [-0.34 (-0.48--0.16), -0.36 (-0.69--0.09), and -0.12 (-0.39-0.05) mm, respectively, NS]. Early intracoronary administration of hematopoietic BM stem cells in patients with previous MI is associated with accelerated luminal loss and reduced conductance of the infarct-related artery.
Similar articles
-
Impact of intracoronary injection of CD133+ bone marrow stem cells on coronary atherosclerotic progression in patients with STEMI: a COMPARE-AMI IVUS substudy.Coron Artery Dis. 2016 Jan;27(1):5-12. doi: 10.1097/MCA.0000000000000302. Coron Artery Dis. 2016. PMID: 26340545 Clinical Trial.
-
Restoration of microvascular function in the infarct-related artery by intracoronary transplantation of bone marrow progenitor cells in patients with acute myocardial infarction: the Doppler Substudy of the Reinfusion of Enriched Progenitor Cells and Infarct Remodeling in Acute Myocardial Infarction (REPAIR-AMI) trial.Circulation. 2007 Jul 24;116(4):366-74. doi: 10.1161/CIRCULATIONAHA.106.671545. Epub 2007 Jul 9. Circulation. 2007. PMID: 17620510 Clinical Trial.
-
Absence of accelerated atherosclerotic disease progression after intracoronary infusion of bone marrow derived mononuclear cells in patients with acute myocardial infarction--angiographic and intravascular ultrasound--results from the TErapia Celular Aplicada al Miocardio Pilot study.Am Heart J. 2010 Jun;159(6):1154.e1-8. doi: 10.1016/j.ahj.2010.03.030. Am Heart J. 2010. PMID: 20569733 Clinical Trial.
-
Intracoronary injection of CD133-positive enriched bone marrow progenitor cells promotes cardiac recovery after recent myocardial infarction: feasibility and safety.Circulation. 2005 Aug 30;112(9 Suppl):I178-83. doi: 10.1161/CIRCULATIONAHA.104.522292. Circulation. 2005. PMID: 16159812 Clinical Trial.
-
Design and rationale for the Myocardial Stem Cell Administration After Acute Myocardial Infarction (MYSTAR) Study: a multicenter, prospective, randomized, single-blind trial comparing early and late intracoronary or combined (percutaneous intramyocardial and intracoronary) administration of nonselected autologous bone marrow cells to patients after acute myocardial infarction.Am Heart J. 2007 Feb;153(2):212.e1-7. doi: 10.1016/j.ahj.2006.10.027. Am Heart J. 2007. PMID: 17239678 Clinical Trial.
Cited by
-
One-Year Safety Analysis of the COMPARE-AMI Trial: Comparison of Intracoronary Injection of CD133 Bone Marrow Stem Cells to Placebo in Patients after Acute Myocardial Infarction and Left Ventricular Dysfunction.Bone Marrow Res. 2011;2011:385124. doi: 10.1155/2011/385124. Epub 2011 Feb 27. Bone Marrow Res. 2011. PMID: 22046562 Free PMC article.
-
Critical Roles of Reactive Oxygen Species in Age-Related Impairment in Ischemia-Induced Neovascularization by Regulating Stem and Progenitor Cell Function.Oxid Med Cell Longev. 2015;2015:7095901. doi: 10.1155/2016/7095901. Epub 2015 Nov 30. Oxid Med Cell Longev. 2015. PMID: 26697140 Free PMC article. Review.
-
Glucose-6-phosphate dehydrogenase plays a critical role in hypoxia-induced CD133+ progenitor cells self-renewal and stimulates their accumulation in the lungs of pulmonary hypertensive rats.Am J Physiol Lung Cell Mol Physiol. 2014 Oct 1;307(7):L545-56. doi: 10.1152/ajplung.00303.2013. Epub 2014 Jul 25. Am J Physiol Lung Cell Mol Physiol. 2014. PMID: 25063801 Free PMC article.
-
Stem cell treatment for acute myocardial infarction.Cochrane Database Syst Rev. 2015 Sep 30;2015(9):CD006536. doi: 10.1002/14651858.CD006536.pub4. Cochrane Database Syst Rev. 2015. PMID: 26419913 Free PMC article. Review.
-
Endothelial progenitor cells in cardiovascular diseases: from biomarker to therapeutic agent.Regen Med Res. 2013 Dec 6;1(1):9. doi: 10.1186/2050-490X-1-9. eCollection 2013 Dec. Regen Med Res. 2013. PMID: 25984328 Free PMC article. Review.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous